Affinage

Showing AOC3 — VAP-1 is a alias.

AOC3

Amine oxidase [copper-containing] 3 · UniProt Q16853

Length
763 aa
Mass
84.6 kDa
Annotated
2026-06-09
100 papers in source corpus 33 papers cited in narrative 33 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

AOC3/VAP-1 is a homodimeric, sialylated cell-surface copper-containing amine oxidase that couples a dual adhesive and enzymatic role in directing leukocyte traffic across endothelium during inflammation (PMID:8627168, PMID:15664163). It mediates shear-resistant, oligosaccharide-dependent binding of CD8+ T cells and NK cells to high endothelial venules independently of L-selectin, and acts as a molecular brake on leukocyte rolling that promotes firm adhesion and transmigration in vivo (PMID:9254657, PMID:10864915, PMID:11156953). Genetic ablation establishes AOC3 as essential for leukocyte slow rolling, firm adhesion, extravasation, lymphocyte homing, and mucosal immunity (PMID:15664163, PMID:17947691). The enzymatic and adhesive functions are mechanistically linked: the TPQ-cofactor-dependent oxidation of primary amines is required for transmigration and drives transcriptional induction of endothelial E- and P-selectins, and oxidase-activity-null knock-in mice phenocopy the full knockout in sterile peritonitis and arthritis, definitively assigning the pro-inflammatory action to catalysis (PMID:14726375, PMID:17548577, PMID:23885334). Mechanistic enzymology and crystallography of the soluble form define a TPQ cofactor with rate-limiting C–H bond cleavage, copper-coordinating active-site geometry, and substrate-specificity residues (Met211, Leu469) within the substrate channel (PMID:21585208, PMID:21737458). In adipose tissue the same oxidase activity mediates amine-substrate-stimulated glucose uptake and an insulin-like metabolic action, with knock-in studies showing enzymatic activity is required for the metabolic phenotype (PMID:17406965, PMID:32712883). A soluble form is generated by metalloprotease-dependent shedding from adipocytes and endothelium and circulates in blood (PMID:9686623, PMID:14968297). AOC3 transcription in smooth muscle cells is driven by myocardin-related transcription factors acting through SRF and KDM3A-dependent chromatin remodeling (PMID:33727640).

Mechanistic history

Synthesis pass · year-by-year structured walk · 30 steps
  1. 1996 High

    Established that VAP-1's adhesive activity toward lymphocytes depends on its heavy sialylation, defining it as a glycosylation-dependent endothelial adhesion molecule before its enzymatic identity was known.

    Evidence Glycosidase digestion plus frozen-section adhesion under shear and mAb blockade

    PMID:8627168

    Open questions at the time
    • Molecular identity of the lymphocyte counter-receptor not defined
    • Relationship between adhesion and any catalytic function not yet addressed
  2. 1997 High

    Demonstrated subtype-specific, L-selectin-independent adhesion of CD8+ T and NK cells to HEVs and confirmed VAP-1 involvement in initial lymphocyte–endothelial contact in vivo.

    Evidence Frozen-section shear adhesion with orthogonal mAb blockade and rabbit intravital microscopy

    PMID:9254657

    Open questions at the time
    • Counter-receptor still unidentified
    • Mechanistic basis of cell-type preference unknown
  3. 1998 Medium

    Identified a circulating soluble form of VAP-1 retaining adhesion-modulating activity, raising the possibility of a regulated shed pool.

    Evidence Sandwich ELISA, reducing/non-reducing immunoblot, and in vitro adhesion assay

    PMID:9686623

    Open questions at the time
    • Mechanism and protease responsible for shedding not defined
    • Physiological role of soluble form unresolved
  4. 2000 High

    Reconstitution by transfection proved VAP-1 is sufficient to confer shear-dependent CD8+ adhesion and showed RGD motif and enzymatic activity are dispensable for adhesion itself, separating adhesion from catalysis.

    Evidence VAP-1 cDNA transfection, flow chamber adhesion, lymphocyte mAb blockade, activity mutagenesis

    PMID:10864915

    Open questions at the time
    • CD44-VAP-1 counter-receptor link inferred but not molecularly mapped
    • Did not reconcile enzyme-independent adhesion with later enzyme-dependent transmigration
  5. 2001 High

    Defined VAP-1 functionally as a molecular brake on granulocyte rolling that converts rolling to firm adhesion and enables extravasation in vivo.

    Evidence Rabbit intravital microscopy with quantitative rolling/adhesion measurements and mAb blockade

    PMID:11156953

    Open questions at the time
    • Did not establish whether enzymatic activity underlies the braking effect
  6. 2004 High

    Showed that the amine oxidase activity is required for PMN transmigration, linking catalysis to leukocyte trafficking for the first time.

    Evidence Enzymatically inactive point mutant, amine oxidase inhibitors, flow transmigration assay, in vivo model

    PMID:14726375

    Open questions at the time
    • Downstream effectors of the oxidase products not identified at this stage
  7. 2004 High

    Identified adipocytes as a source of soluble VAP-1 generated by metalloprotease-dependent shedding regulated by TNF-α and insulin, defining how the soluble pool arises.

    Evidence Adipocyte conditioned-medium immunoprecipitation/SSAO assay with batimastat blockade and in vivo adipose ablation

    PMID:14968297

    Open questions at the time
    • Specific metalloprotease not identified
    • Functional consequence of shed enzyme not resolved here
  8. 2005 High

    Genetic knockout established AOC3 as essential for leukocyte slow rolling, firm adhesion, transmigration, and lymphocyte homing in vivo.

    Evidence AOC3 knockout mice with real-time intravital imaging, peritonitis, and homing assays

    PMID:15664163

    Open questions at the time
    • Did not isolate enzymatic from adhesive contribution genetically
  9. 2007 High

    Connected oxidase activity to a transcriptional output by showing enzyme-dependent induction of endothelial E- and P-selectins, providing a molecular bridge between catalysis and adhesion.

    Evidence WT vs enzyme-null point-mutant endothelial cells, KO and humanized transgenic mice, selectin transcription/translation assays

    PMID:17548577

    Open questions at the time
    • Signaling pathway from H2O2/aldehyde products to selectin transcription not fully mapped
  10. 2007 High

    Extended AOC3 function to mucosal immunity, showing KO mice have reduced IgA, Peyer's patch defects, and impaired oral/antimicrobial responses.

    Evidence AOC3 KO mice with oral immunization, pathogen challenge, and immunoglobulin measurement

    PMID:17947691

    Open questions at the time
    • Cellular mechanism linking VAP-1 to IgA and Peyer's patch development unclear
  11. 2007 High

    Demonstrated that adipocyte AOC3 oxidase activity mediates amine-substrate-stimulated glucose transport via an oxidation-dependent, non-receptor mechanism.

    Evidence AOC3 KO adipocyte hexose transport assays with multiple amine substrates and SSAO activity measurement

    PMID:17406965

    Open questions at the time
    • Molecular link between oxidation products and glucose transporter mobilization not defined
  12. 2008 Medium

    Showed catalytic products of methylamine oxidation can drive vascular smooth muscle cytotoxicity via p53/PUMA/caspase signaling, implicating the enzyme in cell death.

    Evidence Stably transfected SSAO smooth muscle cells with methylamine treatment and apoptotic pathway western blots/caspase assays

    PMID:18348872

    Open questions at the time
    • Overexpression system; physiological substrate concentrations not validated
    • In vivo relevance not established
  13. 2010 High

    Identified histamine as a tissue-selective AOC3 substrate in adipose tissue and revealed that its oxidation restrains a lipolytic effect, distinguishing AOC3 from AOC1.

    Evidence AOC3 KO mice, tissue amine oxidase and lipolysis assays, expression profiling of related enzymes

    PMID:20012150

    Open questions at the time
    • Physiological regulation of histamine oxidation in human adipose not addressed
  14. 2011 High

    Solved crystal structures of soluble human AOC3 and defined active-site/substrate-channel residues governing substrate specificity, providing a structural framework for catalysis and inhibitor design.

    Evidence X-ray crystallography at 2.6/2.95 Å with site-directed mutagenesis and substrate activity assays

    PMID:21585208

    Open questions at the time
    • Structure of the membrane-bound full-length dimer not determined
  15. 2011 High

    Established C–H bond cleavage at the TPQ cofactor as the rate-limiting catalytic step through kinetic isotope effects.

    Evidence Steady-state kinetics with deuterated substrates, pH-rate profiles, QSAR on soluble VAP-1

    PMID:21737458

    Open questions at the time
    • Does not address regulation of catalysis in the cellular membrane context
  16. 2011 High

    Profiled the broad primary-amine substrate range and showed KmO2 approximates interstitial oxygen, linking enzyme kinetics to adipocyte physiology.

    Evidence Purified recombinant human/murine AOC3 kinetics and whole-cell 3T3-L1 adipocyte measurements

    PMID:22238597

    Open questions at the time
    • Identity of the dominant physiological substrate in vivo not resolved
  17. 2011 Medium

    Localized active VAP-1 dimers to endothelial lipid rafts and showed adhesion function is cell-type-context dependent, absent in smooth muscle cells despite higher expression.

    Evidence Stable transfection, lipid raft fractionation, adhesion and enzyme assays

    PMID:21819380

    Open questions at the time
    • Molecular basis of cell-type-specific adhesion competence unexplained
    • Single overexpression system
  18. 2013 High

    Oxidase-activity-null knock-in mice phenocopied full knockout in peritonitis and arthritis, definitively assigning the pro-inflammatory function to catalytic activity.

    Evidence Oxidase-null knock-in mice compared to null mice in two inflammation models

    PMID:23885334

    Open questions at the time
    • Did not address whether residual adhesion contributes in other disease contexts
  19. 2013 Medium

    Implicated VAP-1 in pulmonary metastasis through myeloid cell recruitment, with mechanistic overlap with VCAM-1.

    Evidence Small-molecule VAP-1 inhibitor and VCAM-1 mAb in a murine metastasis model with myeloid quantification

    PMID:23407548

    Open questions at the time
    • Whether enzymatic vs adhesive activity drives this not separated
    • Single lab pharmacological approach
  20. 2013 High

    Distinguished VAP-1's adhesion versus enzymatic contributions in liver inflammation, showing adhesion-blocking mAb reduces CD4 T cell homing while KO abrogates both.

    Evidence Anti-VAP-1 and anti-α4 mAbs, KO mice, Con A hepatitis, intravital microscopy, T cell phenotyping

    PMID:23686782

    Open questions at the time
    • Relative quantitative contribution of adhesion vs catalysis not fully partitioned
  21. 2013 High

    Defined a reversible pyridazinone inhibitor binding site in the active-site channel and rationalized species-specific inhibition, advancing structure-based drug design.

    Evidence Three inhibitor–hVAP-1 crystal structures, homology modeling, human/rodent activity assays

    PMID:24304424

    Open questions at the time
    • In vivo efficacy of these inhibitors not addressed in this study
  22. 2014 Medium

    Linked SSAO/VAP-1 methylamine oxidation to ischemic endothelial death and showed OGD triggers MMP-2-dependent shedding, connecting the enzyme to cerebrovascular injury.

    Evidence Stably transfected endothelial cells under OGD with MMP inhibitors, caspase blots, adhesion assays

    PMID:24503888

    Open questions at the time
    • Overexpression system; endogenous relevance untested
    • MMP-2 as shedding protease shown only pharmacologically
  23. 2014 Medium

    Established bidirectional cross-talk between SSAO/VAP-1 and amyloid-β in cerebral amyloid angiopathy, with both enzyme-dependent and -independent components.

    Evidence Vascular cells stably expressing SSAO, Aβ treatment, enzymatic inhibition, deposition and toxicity assays

    PMID:25457560

    Open questions at the time
    • Enzyme-independent mechanism of Aβ enhancement not defined
    • Overexpression model only
  24. 2016 Medium

    Identified AOC3 as a surface marker of myofibroblasts that is downregulated by TGFβ, distinguishing it from αSMA-defined fibroblast states.

    Evidence mAb PR2D3 target identification, surface protease digestion, FACS, TGFβ treatment, microarray

    PMID:27036009

    Open questions at the time
    • Functional role of AOC3 in myofibroblast biology not established
    • Mechanism of TGFβ regulation unmapped
  25. 2017 Medium

    Showed simvastatin suppresses ischemia-induced soluble SSAO release and selectin/VCAM-1 expression via SSAO-dependent pathways without direct enzyme inhibition.

    Evidence Isogenic SSAO-expressing endothelial cells, in vivo stroke model, activity and adhesion assays

    PMID:29175057

    Open questions at the time
    • Indirect mechanism; statin target intersecting SSAO pathway not defined
  26. 2019 Medium

    Linked endothelial SSAO/VAP-1 to blood-brain-barrier dysfunction through altered cytokine release, tight-junction loss, increased permeability, and Aβ deposition in Alzheimer's models.

    Evidence Isogenic hCMEC/D3 BBB models with cytokine ELISA, tight-junction blots, permeability and adhesion assays

    PMID:31047972

    Open questions at the time
    • In vivo BBB validation lacking
    • Enzyme-independent component mechanistically unresolved
  27. 2020 High

    Demonstrated through parallel KO and oxidase-null knock-in mice that SSAO enzymatic activity is required for VAP-1's adipose metabolic functions, mirroring the inflammatory enzyme-dependence.

    Evidence AOC3 KO vs oxidase-null knock-in mice, body composition, adipocyte glucose transport, inflammation markers

    PMID:32712883

    Open questions at the time
    • Downstream effector linking oxidation to insulin-like glucose uptake not identified
  28. 2021 Medium

    Defined the transcriptional control of AOC3 in smooth muscle cells, identifying it as an MRTF/SRF target dependent on KDM3A-mediated chromatin remodeling.

    Evidence MRTF overexpression, SRF siRNA, promoter-reporter assays, qPCR/western blot in human SMCs

    PMID:33727640

    Open questions at the time
    • Upstream signals activating MRTF/SRF on the AOC3 locus not defined
    • In vivo confirmation lacking
  29. 2022 Medium

    Revealed a paradoxical protective role for AOC3 in early atherosclerosis, where KO increased plaque size and VSMC dedifferentiation, confirming VSMC-dominant expression in plaques.

    Evidence ApoE-/-/AOC3-/- mice, immunohistochemistry, contractile marker blots, human VSMC inhibitor treatment

    PMID:36176983

    Open questions at the time
    • Mechanism by which AOC3 loss promotes VSMC dedifferentiation unresolved
    • Stage-dependence not fully characterized
  30. 2024 Medium

    Showed AOC3 promotes osteosarcoma lung metastasis by recruiting tumor-associated neutrophils and driving NET formation and angiogenesis via NF-κB/IL-8 signaling.

    Evidence AOC3 siRNA knockdown, migration/invasion/tube/sphere assays, xenograft metastasis model, NET imaging

    PMID:39296147

    Open questions at the time
    • Enzymatic vs adhesive contribution not separated
    • Direct AOC3-NF-κB/IL-8 link not mechanistically defined

Open questions

Synthesis pass · forward-looking unresolved questions
  • The molecular identity of the lymphocyte/leukocyte counter-receptor and the precise signaling chain connecting amine-oxidation products (H2O2, aldehyde, ammonia) to selectin induction and glucose transport remain undefined.
  • Counter-receptor for VAP-1-mediated adhesion not molecularly identified
  • Signal transduction from oxidase products to transcriptional and metabolic outputs incompletely mapped
  • Structure of full-length membrane dimer unresolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016491 oxidoreductase activity 7 GO:0098631 cell adhesion mediator activity 5 GO:0016787 hydrolase activity 3
Localization
GO:0005886 plasma membrane 4 GO:0005576 extracellular region 2
Pathway
R-HSA-168256 Immune System 7 R-HSA-1500931 Cell-Cell communication 4 R-HSA-1430728 Metabolism 3

Evidence

Reading pass · 33 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1996 VAP-1 (AOC3) mediates lymphocyte binding to endothelial cells in a sialic acid-dependent manner; desialylation abolishes lymphocyte binding. The mature 170-kDa surface form is a heavily sialylated glycoprotein, and sialic acids are indispensable for VAP-1 adhesive function. Glycosidase digestion of VAP-1, frozen-section adhesion assay under shear stress, anti-VAP-1 monoclonal antibody blockade The Journal of experimental medicine High 8627168
1997 VAP-1 mediates subtype-specific adhesion of CD8+ T cells and NK cells to peripheral lymph node HEVs under shear in an oligosaccharide-dependent, L-selectin-independent manner. Intravital microscopy confirmed VAP-1 involvement in initial lymphocyte–endothelial contact in vivo. Frozen-section adhesion assay under shear, anti-VAP-1/anti-L-selectin/anti-α4 integrin mAb blockade, intravital microscopy in rabbit mesenteric venules The Journal of experimental medicine High 9254657
1998 A soluble form of VAP-1 (sVAP-1) circulates in human blood; it is slightly larger (by ~10 kDa) than membrane-bound VAP-1 under non-reducing conditions but migrates similarly after reduction. Circulating sVAP-1 retains the ability to modulate lymphocyte binding to endothelial cells. Sandwich ELISA with anti-VAP-1 mAbs, immunoblotting under reducing and non-reducing conditions, in vitro lymphocyte adhesion assay Journal of immunology Medium 9686623
2000 Recombinant VAP-1 cDNA transfected into a non-adherent endothelial cell line reconstitutes shear-dependent lymphocyte binding with preference for CD8+ T cells. CD44 ligation on lymphocytes upregulates VAP-1-dependent adhesion, suggesting CD44 activates the VAP-1 counter-receptor. The RGD motif and enzymatic activity are not required for adhesion. VAP-1 cDNA transfection into endothelial cell line, flow chamber and rotatory adhesion assays under shear, antibody blockade of lymphocyte surface molecules, enzymatic activity mutagenesis/inhibition Circulation research High 10864915
2001 VAP-1 functions as a molecular brake during granulocyte rolling in vivo: anti-VAP-1 mAb treatment in rabbits increased rolling velocity, increased rolling skipping frequency, and reduced firm leukocyte adhesion by ~44%, attenuating ~70% of granulocyte extravasation into an inflammation site. Intravital microscopy in rabbit inflammation model, anti-VAP-1 mAb blockade FASEB journal High 11156953
2004 The amine oxidase (enzymatic) activity of VAP-1 is required for PMN transmigration through endothelium: an enzymatically inactive point mutant of VAP-1 abolished transmigration capacity, and specific amine oxidase inhibitors reduced PMN rolling and transmigration under shear stress in vitro and PMN extravasation in vivo. Enzymatically inactive VAP-1 point mutant, amine oxidase inhibitors, flow-dependent in vitro transmigration assay, in vivo animal inflammation model Blood High 14726375
2004 Adipocytes (3T3-L1 cells and human adipose tissue explants) are a source of soluble VAP-1/SSAO generated by metalloprotease-dependent shedding of the membrane form. TNF-α stimulates and insulin modulates this release; metalloprotease inhibitor batimastat blocks it. Detection of sVAP-1 in adipocyte conditioned medium by immunoprecipitation and SSAO activity assay, batimastat (metalloprotease inhibitor) blockade, partial adipose tissue ablation in rats Diabetologia High 14968297
2005 AOC3/VAP-1-deficient mice show defective leukocyte slow rolling, firm adhesion, and transmigration at inflammatory sites and lymphoid tissues, with reduced lymphocyte homing to lymphoid organs and attenuated peritonitis response, establishing AOC3 as essential for leukocyte extravasation in vivo. AOC3 knockout mice, real-time intravital imaging, peritonitis model, lymphocyte homing assay Immunity High 15664163
2006 Fetal VAP-1 is expressed from embryonic week 7 in smooth muscle, is dimerized and enzymatically active before birth, and can mediate rolling and firm adhesion of cord blood lymphocytes on HUVEC under shear stress, indicating the protein is functionally intact during human ontogeny. Immunohistochemistry of fetal tissues, adenoviral VAP-1 transfection of HUVEC, flow chamber adhesion assay with cord blood lymphocytes, enzymatic activity measurement Blood Medium 16556889
2007 The oxidase activity of VAP-1 induces transcription and translation of endothelial E- and P-selectins, thereby promoting leukocyte binding. In VAP-1-deficient mice reconstituted with human VAP-1 transgene, enzyme-dependent P-selectin upregulation was confirmed in HEVs and flat-walled vessels in vivo. Wild-type and enzymatically inactive VAP-1 point mutant transfected endothelial cells, VAP-1 KO mice, humanized VAP-1 transgenic mice, selectin transcription/translation assays, lymphocyte binding assay Blood High 17548577
2007 AOC3/VAP-1-deficient mice have reduced IgA concentrations, age-dependent paucity of Peyer's patch lymphocytes, and impaired oral OVA immunization and antimicrobial responses (S. aureus, coxsackie B4), establishing a role for VAP-1 in mucosal immunity. VAP-1 KO mice, oral immunization with OVA, bacterial/viral challenge, flow cytometry, immunoglobulin measurement Journal of immunology High 17947691
2007 SSAO/VAP-1 oxidizes primary amines in adipocytes; substrates including benzylamine and methylamine stimulate glucose transport via an oxidation-dependent (not receptor-mediated) mechanism. AOC3 knockout adipocytes completely lacked the SSAO-dependent glucose uptake response to benzylamine, methylamine, and tyramine. AOC3 knockout mice, hexose transport assay in isolated adipocytes, SSAO activity measurement Journal of neural transmission High 17406965
2008 SSAO/VAP-1 transmembrane form mediates vascular cell death via methylamine oxidation; the catalytic products activate p53 phosphorylation, induce PUMA-α expression, affect mitochondrial Bcl-2 family proteins, and activate effector caspases, causing cytotoxicity in smooth muscle cells. Stably transfected SSAO-expressing smooth muscle cell line (A7r5), methylamine treatment, cytotoxicity assay, western blot for p53, PUMA-α, Bcl-2 family, caspase activity assays Biochimica et biophysica acta Medium 18348872
2008 VAP-1 deficiency in mice attenuates intestinal ischemia-reperfusion injury and acute lung injury. Both enzymatic inhibitors and a function-blocking mAb in wild-type mice replicate the protective phenotype, establishing the catalytic activity of VAP-1 as responsible for its pro-inflammatory action in I/R injury. VAP-1 KO mice, humanized transgenic VAP-1 mice, small molecule enzyme inhibitors, function-blocking mAb, intestinal I/R model with lung injury readout European journal of immunology High 18991279
2011 Crystal structures of soluble AOC3 from human plasma revealed two imidazole-binding sites: one at the TPQ cofactor (in both off-copper and on-copper conformations) and one in the substrate channel near Tyr394 and Thr212. Single-mutant functional studies identified Met211 and Leu469 as key residues for substrate specificity. X-ray crystallography of soluble human AOC3 (2.6 Å and 2.95 Å resolution), site-directed mutagenesis of Met211, Tyr394, Thr212, Leu469, enzyme activity assays with four substrates, computational docking Biochemistry High 21585208
2011 Human AOC3 expressed in insect cells oxidizes a broad range of primary amines including dopamine and cysteamine; kinetic profiling shows K(m)(O2) approximates interstitial oxygen partial pressure. Differentiated murine 3T3-L1 adipocytes display uniform cell-surface AOC3 with whole-cell K(m) values close to those of purified enzyme, linking kinetic parameters to adipocyte function. Purified recombinant human and murine AOC3 from insect cells, substrate kinetic profiling, K(m)(O2) measurement, whole-cell kinetics with differentiated 3T3-L1 adipocytes PloS one High 22238597
2011 VAP-1 kinetics studied using isotope effects (KIE of 6–7.6 on k(cat)/K(m) with d2-benzylamine; large KIE on k(cat) ~8 with phenylethylamine) established that C-H bond breaking at the TPQ cofactor is the rate-limiting step for substrate oxidation. Soluble VAP-1 expressed in HEK293 EBNA1 cells, steady-state kinetics, primary kinetic isotope effects with deuterated substrates, pH-rate profiles, QSAR analysis The Journal of biological chemistry High 21737458
2011 VAP-1 expressed in endothelial cells localizes specifically to lipid rafts of the plasma membrane as a dimer, retains enzymatic activity comparable to in vivo, and mediates leukocyte adhesion to endothelium; this adhesion function is not observed in smooth muscle cell lines expressing 3-fold higher VAP-1, indicating cell-type-specific functional context. Stable transfection of human SSAO/VAP-1 into endothelial cell line, lipid raft fractionation, western blot, leukocyte adhesion assay, SSAO enzyme activity assay Biology of the cell Medium 21819380
2011 VAP-1 inhibition blocks IL-1β-induced but not VEGF-A-induced lymphangiogenesis and angiogenesis in the mouse cornea, and this effect is mediated by blockade of M2 macrophage infiltration. VAP-1 was expressed in blood vessels but not in lymphatic vessels in vivo. Corneal micropocket assay with IL-1β or VEGF-A, VAP-1 inhibitor treatment, in vivo molecular imaging of VAP-1 expression, macrophage phenotyping The American journal of pathology Medium 21435467
2013 Mice carrying an oxidase-activity-null VAP-1 knock-in show the same inflammatory phenotype as VAP-1 null mice in sterile peritonitis and antibody-induced arthritis models, definitively establishing that the oxidase activity is responsible for VAP-1's pro-inflammatory function in vivo. VAP-1 oxidase-null knock-in mice, sterile peritonitis model, antibody-induced arthritis model, comparison to VAP-1 null mice American journal of clinical and experimental immunology High 23885334
2013 VAP-1 mediates myeloid cell recruitment during pulmonary metastasis; blocking VAP-1 with a small molecule inhibitor reduces myeloid cell accumulation, tumor cell survival, and metastasis. Simultaneous blockade of VCAM-1 and VAP-1 does not produce additive effects, suggesting closely related mechanisms. VAP-1 small molecule inhibitor, VCAM-1 blocking antibody, murine pulmonary metastasis model, myeloid cell quantification, tumor survival assay Blood Medium 23407548
2013 VAP-1 and α4 integrin mediate opposing immune cell recruitment in concanavalin A hepatitis: anti-VAP-1 antibody (blocking adhesion but not amine oxidase activity) reduces IL-4-producing CD4 T cell infiltration and liver injury, while VAP-1-deficient mice show complete abrogation of both activities, confirming VAP-1-dependent CD4 T cell homing to the liver. Anti-VAP-1 mAb, anti-α4 integrin mAb, VAP-1 KO mice, Con A hepatitis model, intravital microscopy, T cell phenotyping Hepatology High 23686782
2013 Crystal structures of novel pyridazinone inhibitors in complex with human VAP-1 defined a unique reversible binding site in the active site channel distinct from covalent substrate-based binding; homology modeling identified species-specific amino acid differences explaining the lack of rodent VAP-1 inhibition. X-ray crystallography of inhibitor–hVAP-1 complexes (3 structures), homology modeling, inhibitory activity assays against human and rodent VAP-1 Journal of medicinal chemistry High 24304424
2014 SSAO/VAP-1 in endothelial cells exacerbates oxygen-glucose deprivation (OGD) damage; methylamine oxidation during OGD increases cell death via caspase-3 and caspase-8 activation. OGD also triggers metalloproteinase-2-dependent shedding of soluble SSAO/VAP-1 and induces SSAO-dependent leukocyte adhesion partly through its enzymatic activity. Stably transfected hSSAO/VAP-1 endothelial cell line, OGD model, metalloproteinase inhibitors, western blot for caspases, leukocyte adhesion assay, SSAO enzymatic substrate treatment Cerebrovascular diseases Medium 24503888
2014 SSAO/VAP-1 enhances Aβ1-40 (Dutch mutant) and Aβ1-42 deposition on vascular cells by mechanisms both dependent and independent of its enzymatic activity. Conversely, Dutch-mutated Aβ1-40 increases SSAO-dependent cell toxicity and increases SSAO protein availability at endothelial membranes, establishing a bidirectional cross-talk between SSAO and Aβ in CAA pathology. Vascular cell models stably expressing SSAO, Aβ peptide treatment, SSAO enzymatic activity inhibition, Aβ deposition quantification, cell toxicity assay Neurobiology of aging Medium 25457560
2019 SSAO/VAP-1 expression in endothelial cells alters the pro-inflammatory and pro-angiogenic angioneurin release (particularly IL-6, IL-8, VEGF), decreases tight-junction proteins (zona occludens, claudin-5), increases BBB permeability and leukocyte adhesion, and enhances vascular Aβ deposition by mechanisms both dependent and independent of enzymatic activity, linking SSAO to BBB dysfunction in Alzheimer's disease. In vitro BBB models (hCMEC/D3 cells expressing or not expressing hSSAO/VAP-1), cytokine ELISA, western blot for tight-junction proteins, permeability assay, leukocyte adhesion assay, Aβ deposition assay Biochimica et biophysica acta. Molecular basis of disease Medium 31047972
2020 The obesity phenotype of AOC3 knockout mice (increased adiposity, loss of benzylamine insulin-like action in adipocytes, downregulated adipose inflammatory markers) is fully reproduced in AOC3 knock-in mice expressing oxidase-activity-null VAP-1, establishing that the SSAO enzymatic activity is required for the metabolic functions of VAP-1 in adipose tissue. AOC3 KO mice vs. AOC3 oxidase-activity knock-in mice, body composition, adipocyte glucose transport assay, lipid profile, adipose tissue inflammation markers, SSAO activity measurement Journal of physiology and biochemistry High 32712883
2021 AOC3/VAP-1 is a transcriptional target of myocardin-related transcription factors (MRTFs: MYOCD, MRTF-A/MKL1, MRTF-B/MKL2) acting through serum response factor (SRF) in smooth muscle cells. MRTF overexpression increases AOC3 mRNA and protein; SRF silencing reduces AOC3 transcript levels; AOC3 promoter reporter activity is increased by MRTF-A and depends on chromatin remodeling enzyme KDM3A. Bioinformatics correlation, MRTF overexpression in human SMCs, SRF siRNA knockdown, promoter-reporter assay, qPCR, western blot, immunofluorescence imaging Scientific reports Medium 33727640
2010 In mouse adipose tissue, histamine is oxidized predominantly by SSAO (AOC3 product): AOC3 knockout abolished histamine oxidation in adipose tissue but not in intestine, where diamine oxidase (AOC1) predominates. Loss of adipose SSAO-mediated histamine oxidation unmasked a lipolytic effect of histamine in adipocytes. AOC3 KO mice, tissue amine oxidase activity assay (hydrogen peroxide production), lipolysis assay (glycerol release) in isolated adipocytes, real-time PCR for AOC1/AOC2/MAOA/MAOB Inflammation research High 20012150
2016 AOC3 is a marker of myofibroblasts (identified as the target of mAb PR2D3) and is expressed on the cell surface in a trypsin- and collagenase-sensitive manner. TGFβ substantially downregulates AOC3 expression in myofibroblasts but dramatically increases αSMA in skin fibroblasts, distinguishing these two cell types. Identification of AOC3 as mAb PR2D3 target protein, surface trypsin/collagenase digestion assay, FACS sorting, TGFβ treatment, whole-genome microarray, NKX2-3 knockdown, qPCR/western blot Proceedings of the National Academy of Sciences of the United States of America Medium 27036009
2022 AOC3 knockout in ApoE-/- mice paradoxically increased atherosclerotic plaque size at early stages, associated with VSMC dedifferentiation, decreased contractile markers, increased MCP-1, and higher CD3+ T cell recruitment. AOC3 was confirmed to be expressed mainly by VSMCs and slightly by endothelium, but not by macrophages in plaques. ApoE-/-/AOC3-/- double knockout mice, immunohistochemistry, western blot, confocal microscopy, qPCR, human VSMC treatment with AOC3 inhibitor LJP1586 Frontiers in cardiovascular medicine Medium 36176983
2024 AOC3 promotes lung metastasis of osteosarcoma by recruiting tumor-associated neutrophils; activated neutrophil extracellular traps (NETs) upregulate metastatic capacity of OS cells, and AOC3 also supports tumor neovascularization. Downregulation of AOC3 inhibits OS cell migration, invasion, and angiogenesis in vitro and reduces lung metastasis in vivo, mediated through NF-κB/IL-8 signaling. siRNA knockdown of AOC3 in OS cells, transwell/wound healing assay, tube formation assay, sphere-forming assay, C57BL/6 xenograft lung metastasis model, flow cytometry for neutrophil recruitment, immunofluorescence for NETs, ELISA Heliyon Medium 39296147
2017 Simvastatin blocks soluble SSAO/VAP-1 release into the bloodstream after ischemic stimulus and prevents E-selectin and VCAM-1 overexpression, in part through interaction with SSAO/VAP-1-dependent pathways, while not acting as a direct enzymatic inhibitor of SSAO in vitro. In vitro ischemia model in hSSAO/VAP-1-expressing endothelial cells, in vivo stroke model, SSAO activity assay, western blot for E-selectin and VCAM-1, leukocyte adhesion assay Biochimica et biophysica acta. Molecular basis of disease Medium 29175057

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2006 Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. The EMBO journal 151 16688218
2001 VAP-1: an adhesin and an enzyme. Trends in immunology 134 11274927
1998 Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. Journal of immunology (Baltimore, Md. : 1950) 131 9686623
2005 Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 107 15664163
2004 Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 107 14726375
2004 Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner. Diabetologia 99 14968297
2007 VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arteriosclerosis, thrombosis, and vascular biology 93 17962625
1996 Human vascular adhesion protein 1 (VAP-1) is a unique sialoglycoprotein that mediates carbohydrate-dependent binding of lymphocytes to endothelial cells. The Journal of experimental medicine 90 8627168
2007 The oxidase activity of vascular adhesion protein-1 (VAP-1) induces endothelial E- and P-selectins and leukocyte binding. Blood 88 17548577
1997 Vascular adhesion protein 1 (VAP-1) mediates lymphocyte subtype-specific, selectin-independent recognition of vascular endothelium in human lymph nodes. The Journal of experimental medicine 85 9254657
2016 Myofibroblasts are distinguished from activated skin fibroblasts by the expression of AOC3 and other associated markers. Proceedings of the National Academy of Sciences of the United States of America 83 27036009
2001 Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates recruitment in vivo. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 72 11156953
2013 VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice. Blood 71 23407548
1996 Lymphocyte binding to vascular endothelium in inflamed skin revisited: a central role for vascular adhesion protein-1 (VAP-1). European journal of immunology 59 8625974
2010 Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke. Stroke 58 20538694
2015 Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration. Respiratory research 50 25889951
2013 PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo. The Journal of pharmacology and experimental therapeutics 44 23943052
2011 VAP-1-mediated M2 macrophage infiltration underlies IL-1β- but not VEGF-A-induced lymph- and angiogenesis. The American journal of pathology 43 21435467
2000 Human vascular adhesion protein-1 (VAP-1) plays a critical role in lymphocyte-endothelial cell adhesion cascade under shear. Circulation research 38 10864915
2005 Properties of recombinant human N1-acetylpolyamine oxidase (hPAO): potential role in determining drug sensitivity. Cancer chemotherapy and pharmacology 37 15791459
2004 A peptide inhibitor of vascular adhesion protein-1 (VAP-1) blocks leukocyte-endothelium interactions under shear stress. European journal of immunology 37 15259025
2006 Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis. Journal of neuroimmunology 35 16806498
1995 Different forms of human vascular adhesion protein-1 (VAP-1) in blood vessels in vivo and in cultured endothelial cells: implications for lymphocyte-endothelial cell adhesion models. European journal of immunology 35 7589075
2012 Implication for functions of the ectopic adipocyte copper amine oxidase (AOC3) from purified enzyme and cell-based kinetic studies. PloS one 34 22238597
2011 VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke. Cerebrovascular diseases (Basel, Switzerland) 33 22133888
2015 VAP-1 blockade prevents subarachnoid hemorrhage-associated cerebrovascular dilating dysfunction via repression of a neutrophil recruitment-related mechanism. Brain research 32 25662771
2009 Circulating form of human vascular adhesion protein-1 (VAP-1): decreased serum levels in progression of colorectal cancer and predictive marker of lymphatic and hepatic metastasis. Journal of surgical oncology 30 19204971
2007 Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients. Journal of the European Academy of Dermatology and Venereology : JEADV 30 17207171
2012 The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1). Bioorganic & medicinal chemistry letters 29 22595173
2008 Ischemia-reperfusion injury is attenuated in VAP-1-deficient mice and by VAP-1 inhibitors. European journal of immunology 29 18991279
2013 Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1): old target-new inhibition mode. Journal of medicinal chemistry 28 24304424
2011 Mini-PEG spacering of VAP-1-targeting 68Ga-DOTAVAP-P1 peptide improves PET imaging of inflammation. EJNMMI research 28 22214508
2007 VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: effects of statins. Experimental and molecular pathology 28 17490641
2019 Blood-brain barrier dysfunction underlying Alzheimer's disease is induced by an SSAO/VAP-1-dependent cerebrovascular activation with enhanced Aβ deposition. Biochimica et biophysica acta. Molecular basis of disease 26 31047972
2013 Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment. Bioorganic & medicinal chemistry 26 23664164
2013 The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. American journal of clinical and experimental immunology 26 23885334
2011 Identification of two imidazole binding sites and key residues for substrate specificity in human primary amine oxidase AOC3. Biochemistry 25 21585208
2008 p53 phosphorylation is involved in vascular cell death induced by the catalytic activity of membrane-bound SSAO/VAP-1. Biochimica et biophysica acta 25 18348872
2021 SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease. International journal of molecular sciences 24 33805974
2009 Localization of vascular adhesion protein-1 (VAP-1) in the human eye. Experimental eye research 24 19761765
2006 Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans. Blood 24 16556889
2021 Vascular Adhesion Protein-1 (VAP-1)/Semicarbazide-Sensitive Amine Oxidase (SSAO): A Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseases. Frontiers in pharmacology 23 34322017
2007 VAP-1-deficient mice display defects in mucosal immunity and antimicrobial responses: implications for antiadhesive applications. Journal of immunology (Baltimore, Md. : 1950) 23 17947691
2006 New efficient substrates for semicarbazide-sensitive amine oxidase/VAP-1 enzyme: analysis by SARs and computational docking. Journal of medicinal chemistry 23 17034126
2001 Vascular adhesion protein-1 (VAP-1) mediates lymphocyte-endothelial interactions in chronic kidney rejection. European journal of immunology 23 11592062
2016 Evaluation of serum and tissue levels of VAP-1 in colorectal cancer. BMC cancer 21 26912327
2011 Homing-associated molecules CD73 and VAP-1 as targets to prevent harmful inflammations and cancer spread. FEBS letters 21 21515268
2010 A structure-activity study to identify novel and efficient substrates of the human semicarbazide-sensitive amine oxidase/VAP-1 enzyme. Biochimie 21 20298739
2011 Vascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseases. Biology of the cell 20 21819380
2022 Vascular adhesion protein-1 (VAP-1) in vascular inflammatory diseases. VASA. Zeitschrift fur Gefasskrankheiten 19 36200383
2020 Obesity of mice lacking VAP-1/SSAO by Aoc3 gene deletion is reproduced in mice expressing a mutated vascular adhesion protein-1 (VAP-1) devoid of amine oxidase activity. Journal of physiology and biochemistry 19 32712883
2014 Cross-talk between Aβ and endothelial SSAO/VAP-1 accelerates vascular damage and Aβ aggregation related to CAA-AD. Neurobiology of aging 19 25457560
2012 VAP-1, a novel molecule linked to endothelial damage and kidney function in kidney allograft recipients. Kidney & blood pressure research 19 23154672
2014 Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia. Cerebrovascular diseases (Basel, Switzerland) 18 24503888
2014 Endothelial amine oxidase AOC3 transiently contributes to adaptive immune responses in the airways. European journal of immunology 16 25116373
2013 Therapeutic advantage of anti-VAP-1 over anti-α4 integrin antibody in concanavalin a-induced hepatitis. Hepatology (Baltimore, Md.) 16 23686782
2021 Amine oxidase copper-containing 3 (AOC3) inhibition: a potential novel target for the management of diabetic retinopathy. International journal of retina and vitreous 15 33845913
2017 Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control. Biochimica et biophysica acta. Molecular basis of disease 15 29175057
2010 Human vascular adhesion proteın-1 (VAP-1): serum levels for hepatocellular carcinoma in non-alcoholic and alcoholic fatty liver disease. World journal of surgical oncology 15 20849600
2007 Semicarbazide-sensitive amine oxidase substrates fail to induce insulin-like effects in fat cells from AOC3 knockout mice. Journal of neural transmission (Vienna, Austria : 1996) 15 17406965
2005 The release of soluble VAP-1/SSAO by 3T3-L1 adipocytes is stimulated by isoproterenol and low concentrations of TNFalpha. Journal of physiology and biochemistry 15 16180338
2019 Vascular Adhesion Protein-1 (VAP-1) as Predictor of Radiographic Severity in Symptomatic Knee Osteoarthritis in the New York University Cohort. International journal of molecular sciences 14 31146362
2015 Protective effect of the multitarget compound DPH-4 on human SSAO/VAP-1-expressing hCMEC/D3 cells under oxygen-glucose deprivation conditions: an in vitro experimental model of cerebral ischaemia. British journal of pharmacology 14 26362823
2014 Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 14 25279492
2012 Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema. Bioorganic & medicinal chemistry 14 23337801
2022 Downregulation of VAP-1 in OSCC suppresses tumor growth and metastasis via NF-κB/IL-8 signaling and reduces neutrophil infiltration. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 13 35174543
2019 Assessment of relationship between serum vascular adhesion protein-1 (VAP-1) and gestational diabetes mellitus. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 13 31638437
2013 Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema: part 2. Bioorganic & medicinal chemistry 13 23540955
2011 Reaction of vascular adhesion protein-1 (VAP-1) with primary amines: mechanistic insights from isotope effects and quantitative structure-activity relationships. The Journal of biological chemistry 13 21737458
2009 Structure-activity relationships of SSAO/VAP-1 arylalkylamine-based substrates. ChemMedChem 13 19266512
2021 NG2/CSPG4, CD146/MCAM and VAP1/AOC3 are regulated by myocardin-related transcription factors in smooth muscle cells. Scientific reports 12 33727640
2019 Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection. Journal of clinical medicine 12 30658395
2012 Benzylamine antihyperglycemic effect is abolished by AOC3 gene invalidation in mice but not rescued by semicarbazide-sensitive amine oxidase expression under the control of aP2 promoter. Journal of physiology and biochemistry 12 22547093
2007 Characterization of A7r5 cell line transfected in a stable form by hSSAO/VAP-1 gene (A7r5 hSSAO/VAP-1 cell line). Journal of neural transmission (Vienna, Austria : 1996) 11 17393062
2005 Severe cell fragmentation in the endothelial cell apoptosis induced by snake apoptosis toxin VAP1 is an apoptotic characteristic controlled by caspases. Toxicon : official journal of the International Society on Toxinology 10 15922392
2008 Expression of mRNAs coding for VAP1/crotastatin-like metalloproteases in the venom glands of three South American pit vipers assessed by quantitative real-time PCR. Toxicon : official journal of the International Society on Toxinology 9 18926840
2007 L-lysine as a recognition molecule for the VAP-1 function of SSAO. Journal of neural transmission (Vienna, Austria : 1996) 9 17393063
2005 VAP1, with cystatin C motif, an oocyte protein encoded by a novel ovarian-specific gene during oogenesis in the common brushtail possum (Trichosurus vulpecula). Molecular reproduction and development 8 15736124
2015 Assessment of the Relationship Between Serum Vascular Adhesion Protein-1 (VAP-1) and Severity of Calcific Aortic Valve Stenosis. The Journal of heart valve disease 7 27997774
2024 AOC3 accelerates lung metastasis of osteosarcoma by recruiting tumor-associated neutrophils, neutrophil extracellular trap formation and tumor vascularization. Heliyon 6 39296147
2020 Circulating vascular adhesion protein-1(VAP-1): a possible biomarker for liver fibrosis associated with chronic hepatitis B and C. Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] 6 32959205
2023 Identification of AOC3 and LRRC17 as Colonic Fibroblast Activation Markers and Their Potential Roles in Colorectal Cancer Progression. Asian Pacific journal of cancer prevention : APJCP 5 37774061
2018 Effector gene vap1 based DGGE fingerprinting to assess variation within and among Heterodera schachtii populations. Journal of nematology 5 31094153
2010 Histamine oxidation in mouse adipose tissue is controlled by the AOC3 gene-encoded amine oxidase. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 5 20012150
2024 Association Between Vascular Adhesion Protein-1 (VAP-1) and MACE in Patients with Coronary Heart Disease: A Cohort Study. Journal of inflammation research 4 38855169
2022 Increased atherosclerotic plaque in AOC3 knock-out in ApoE-/- mice and characterization of AOC3 in atherosclerotic human coronary arteries. Frontiers in cardiovascular medicine 4 36176983
2015 Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition. Journal of physiology and biochemistry 4 25572340
2013 Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model. Journal of neural transmission (Vienna, Austria : 1996) 4 23397320
2025 Therapeutic Potential of Vascular Adhesion Protein-1 (VAP-1)/Semicarbazide-Sensitive Amine Oxidase (SSAO) Inhibitors: Current Medicinal Chemistry and Emerging Opportunities. Medicinal research reviews 3 40396328
2025 The role of VAP-1 in cardiovascular disease: a review. Frontiers in cardiovascular medicine 3 40458597
2023 ω-(5-Phenyl-2H-tetrazol-2-yl)alkyl-substituted glycine amides and related compounds as inhibitors of the amine oxidase vascular adhesion protein-1 (VAP-1). Bioorganic & medicinal chemistry 3 38142562
2022 ω-(5-Phenyl-2H-tetrazol-2-yl)alkyl-substituted hydrazides and related compounds as inhibitors of amine oxidase copper containing 3 (AOC3). Archiv der Pharmazie 3 35507758
1992 A novel vesicle-associated protein (VAP-1) in sea urchin eggs containing multiple RNA-binding consensus sequences. Journal of cell science 3 1478972
2024 The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses. Frontiers in pharmacology 2 38741586
2024 Amine Oxidase, Copper Containing 3 (Aoc3) Knockout Mice Are More Prone to DSS-induced Colitis and Colonic Tumorigenesis. In vivo (Athens, Greece) 1 39187313
2013 VAP-1 in peritoneally dialyzed patients. Postepy higieny i medycyny doswiadczalnej (Online) 1 24379274
2006 [Vascular adhesion protein-1 (VAP-1) in inflammatory process]. Przeglad lekarski 1 17083159
2025 Association of <italic>AOC3</italic> Expression in Visceral Adipose Tissue and Circulating Soluble Vascular Adhesion Protein-1 with Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Japanese Patients with Severe Obesity. Obesity facts 0 40716438
2025 Pan-cancer analysis reveals AOC3 as a potential therapeutic biomarker for colorectal cancer. Discover oncology 0 41021158
2025 Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [68Ga]Ga-DOTA-Siglec-9. Respiratory research 0 41420234

Missed literature

Know a paper Affinage missed for AOC3? Flag it for the maintainers and the community.

No submissions yet.